3521 Investment Blvd
About Paragon Genomics
Headquartered in Hayward, CA, Paragon Genomics is a dynamic and growing company developing and commercializing breakthrough target enrichment solutions for Next-Generation Sequencing (NGS). We are building a team of best-in-class scientists, engineers and business professionals that thrive in a collaborative entrepreneurial environment. Our patented CleanPlex® technology solves the urgent throughput and efficiency bottlenecks of NGS target enrichment workflow and is applicable to many fast-growing markets in the genomics space. The Company was selected by a distinguished panel into the California Life Science Association F.A.S.T.Program in March 2016 and was accepted into the prestigious Stanford StartX Medicine Accelerator Program in September 2016.
13 articles with Paragon Genomics
New CleanPlex® ACE2 & TMPRSS2 Panel Assesses Differences in Patients' Genetic Susceptibility to COVID-19 Infection and to Developing Severe Disease
Paragon Genomics Readies Higher Throughput Version of Its Popular CleanPlex® SARS-CoV-2 NGS Panel Amid Growing Need for Large-Scale COVID-19 Testing
Multiplexed Target Enrichment Panel Sequences the Entire Viral Genome for High Coverage of Target Regions, Better Accuracy and Mutation Tracking
A summary of daily biopharma industry news. Please check out stories that are trending on March 26, 2020.
Paragon Genomics Introduces CleanPlex® SARS-CoV-2 NGS Panel for Research and Surveillance of COVID-19 Coronavirus
Highly Multiplexed Target Enrichment Panel Covers Entire Genome of the New Coronavirus to Facilitate Complete Genome Sequencing and Support Epidemiological Studies
Paragon Genomics, Inc., a leader in amplicon-based target enrichment solutions for next-generation sequencing (NGS) and precision medicine, today announced that it will present at Biotech Showcase™ 2020, to be held January 13–15, 2020 at the Hilton San Francisco Union Square. Paragon Genomics CEO Tao Chen will give a corporate presentation and meet with investors.
Paragon Genomics Introduces CleanPlex® Cftr Panel And Unveils New Fusion Detection Methods At AMP 2019 Annual Meeting
New CleanPlex® CFTR Targeted Resequencing Assay Simplifies Evaluation of Somatic and Germline CFTR Mutations and Variants, Enabling Comprehensive Assessment in Cystic Fibrosis with Reduced Sample Input, Greater Ease of Use and more Efficient Workflow
Paragon Genomics Introduces New CleanPlex® Hereditary Cancer Panel V2 At American Society For Human Genetics 2019 Annual Meeting
Improved Version of Hereditary Cancer Panel Facilitates Same-Day Risk Assessment of Multiple Hereditary Cancers with Reduced Sample Input, Greater Ease of Use and 3-Hour Workflow
Paragon Genomics Establishes Subsidiary to Market Its Advanced CleanPlex® NGS Target Enrichment Solutions in China
Paragon Genomics, Inc. announced it has established a subsidiary in China to market its CleanPlex® products to the rapidly growing Chinese market.
Paragon Genomics Partners With MGI Tech To Distribute Its CleanPlex® NGS Target Enrichment Panels Worldwide
Subsidiary of BGI Group Will Distribute CleanPlex® NGS Target Enrichment Panels Optimized for Its MGISEQ and BGISEQ Sequencing Platforms in All Territories Outside the U.S.
Paragon Genomics Partners Its Ultra-High Multiplexed Target Enrichment Technology With SOPHiA GENETICS For Comprehensive Genomic Solutions
Universal SOPHiA AI Platform Now Includes Paragon Genomics' Accurate and Sensitive CleanPlex® NGS Target Enrichment Technology for Its Rapidly-Growing Global Community of Cancer Centers
Paragon Genomics Introduces CleanPlex® UMI Panel for Ultrafast, Precise Analysis of Lung Cancer Hotspot Mutations at ASHG 2018
First Product in Family of New CleanPlex® UMI NGS Panels that Deliver Highly Accurate Results in Detecting Low-Frequency Variants and Mutations for Liquid Biopsy and Other Applications
Paragon Genomics Launches ParagonDesigner™ Online Tool that MAKES IT Easy TO Design Custom CleanPlex® NGS Assays
Custom NGS Panels for Illumina and Ion Torrent Platforms Use Paragon Genomics' CleanPlex® Technology that Enables Interrogation of a Large Number of Targets in a Single Assay